Related Experiment Videos
Use of locally delivered conventional drug therapies
E Camenzind1, M J Kutryk, P W Serruys
1Cathelerization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
Insights
Coronary artery restenosis after angioplasty is a significant problem. Local drug delivery strategies show promise for preventing restenosis by reducing neointimal proliferation.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Coronary artery restenosis is a primary limitation following balloon angioplasty, affecting 30-50% of procedures.
- Restenosis involves thrombosis, neointimal proliferation, and vessel remodeling.
- Systemic pharmacotherapy has proven ineffective in human trials for preventing restenosis.
Purpose of the Study:
- To review the pathophysiology of coronary artery restenosis.
- To evaluate the effectiveness of local drug delivery strategies for preventing restenosis.
- To highlight advancements in pharmacological agents and delivery systems.
Main Methods:
- Review of existing literature on coronary artery restenosis pathophysiology.
- Analysis of studies investigating local pharmacotherapy administration.
- Examination of clinical trials for drug-eluting devices.
Main Results:
- Local administration of various compounds (e.g., heparin, cytochalasin B) reduced neointimal formation in animal models.
- Clinical trials confirmed the feasibility of local heparin delivery via InfusaSleeve and Dispatch catheters.
- Preliminary data suggests heparin's long-term efficacy in preventing restenosis when delivered by the Dispatch device.
Conclusions:
- Local drug delivery represents a promising strategy for preventing coronary artery restenosis.
- Ongoing trials with agents like cytochalasin B and improved delivery systems are expected to yield further advancements.
- Continued research into restenosis pathophysiology and targeted therapies is crucial.
Abstract:
Coronary artery restenosis remains the major limitation of balloon angioplasty and occurs in 30-50% of initially successful procedures. Our current understanding of pathophysiology of restenosis suggests that it involves three inter-related phases; (1) acute effects of thrombosis, (2) neointimal proliferation, and (3) acute recoil and chronic remodelling. In an attempt to prevent vessel restenosis both systemic and site-specific pharmacotherapy have been investigated. Although successful in animal models, systemically administered pharmacological agents for the prevention of restenosis in humans have not been effective. The local administration of compounds such as heparin, anti-thrombin agents, colchicine, angiopeptin, antineoplastic agents, calcium antagonists, nitrates, forskolin, cytochalasin B, protein kinase inhibitors and dexamethasone have been shown to reduce neointimal formation in animal models of restenosis. Clinical trials have demonstrated the feasibility of the local administration of heparin using both InfusaSleeve and Dispatch drug delivery catheters. Preliminary results on long-term prevention of restenosis by heparin appear promising using the Dispatch delivery device. In addition, a multicentre trial investigating the effectiveness of cytochalasin B delivered using the Microporous Infusion Catheter for the prevention of restenosis is currently underway. Rapid progress in our understanding of the complex pathophysiology of restenosis and the development of more effective pharmacological agents and atraumatic site specific delivery modalities ensure a promising future for local delivery strategies.